- Home
- ASC vs PRTA Comparison
ASC vs PRTA Comparison
Compare ASC & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASC | PRTA |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | Bermuda | Ireland |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.0M | 495.8M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | ASC | PRTA |
|---|---|---|
| Price | $11.55 | $8.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $13.67 | ★ $18.86 |
| AVG Volume (30 Days) | 617.9K | ★ 673.4K |
| Earning Date | 02-12-2026 | 02-19-2026 |
| Dividend Yield | ★ 7.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $309,326,000.00 | $11,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $819.08 |
| P/E Ratio | $15.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.32 | $4.32 |
| 52 Week High | $13.56 | $16.67 |
Technical Indicators
Market Signals| Indicator | ASC | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 41.49 |
| Support Level | N/A | $8.65 |
| Resistance Level | N/A | $9.26 |
| Average True Range (ATR) | 0.00 | 0.34 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 33.65 |
Price Performance
Historical ComparisonAbout ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.